ClinVar Miner

Submissions for variant NM_005732.4(RAD50):c.2647C>T (p.Arg883Cys) (rs138749920)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000212919 SCV000149853 uncertain significance not provided 2014-02-11 criteria provided, single submitter clinical testing RAD50 has been only recently described in association with cancer predisposition and the risks are not well understood. This variant is denoted RAD50 c.2647C>T at the cDNA level, p.Arg883Cys (R883C) at the protein level, and results in the change of an Arginine to a Cysteine (CGT>TGT). This variant has not, to our knowledge, been published in the literature as pathogenic or benign. RAD50 Arg883Cys was not observed at a significant allele frequency in the NHLBI Exome Sequencing Project. This variant is a non-conservative substitution in which a positive polar amino acid is replaced with a neutral polar one, altering a position that is moderately conserved throughout evolution and is not located in a known functional domain. Multiple in silico algorithms predict that this variant may be damaging to protein structure and function. On a molecular level, the impact of this missense variant on protein structure and function is not known and thus we consider this to be a variant of uncertain significance. Furthermore, based on the currently available information, cancer risks associated with this variant, and the RAD50 gene, remain unclear.
Ambry Genetics RCV000115944 SCV000183924 likely benign Hereditary cancer-predisposing syndrome 2019-02-11 criteria provided, single submitter clinical testing Other data supporting benign classification
Invitae RCV000115944 SCV000254891 benign Hereditary cancer-predisposing syndrome 2020-12-04 criteria provided, single submitter clinical testing
Fulgent Genetics,Fulgent Genetics RCV000515220 SCV000611513 uncertain significance Nijmegen breakage syndrome-like disorder 2017-05-23 criteria provided, single submitter clinical testing
Department of Pathology and Laboratory Medicine,Sinai Health System RCV000212919 SCV001552795 likely benign not provided no assertion criteria provided clinical testing The RAD50 p.Arg883Cys variant was identified in the literature however the frequency of this variant in an affected population was not provided. The variant was also identified in dbSNP (ID: rs138749920) as Uncertain Significance and likely Benign, ClinVar (Reported as Likely Benign by Ambry in 2018, Likely benign by Invitae in 2017, Uncertain significance by Fulgent in 2017, Uncertain significance by GeneDx in 2014), Clinvitae (Likely benign [Invitae], Uncertain significance [ClinVar]), databases. The variant was not identified in Cosmic or LOVD 3.0, databases. The variant was identified in control databases in 152 of 282540 chromosomes (1 homozygous) at a frequency of 0.000538 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: Ashkenazi Jewish in 82 of 10366 chromosomes (freq: 0.00791), South Asian in 29 of 30584 chromosomes (freq: 0.000948), Other in 5 of 7206 chromosomes (freq: 0.000694), Latino in 12 of 35384 chromosomes (freq: 0.000339), European (non-Finnish) in 21 of 128990 chromosomes (freq: 0.000163), African in 2 of 24956 chromosomes (freq: 0.00008), East Asian in 1 of 19950 chromosomes (freq: 0.00005), while the variant was not observed in the and European (Finnish) populations. The p.Arg883C variant was reported as a variant of uncertain significance in a population of 278 BRCA1/2 negative patients with early onset breast cancer who received sequencing of 22 cancer susceptibility genes (Maxwell_2015_PMID: 25503501). The p.Arg883Cys variant was also reported as a variant of uncertain significance in a population of 1040 cancer patients who received germline analysis of 76 cancer predisposition genes (Mandelker_2017_PMID: 23555315). The p.Arg883Cys variant was also identified through genotyping 191,032 common and rare non-synonymous, splice site, or nonsense variants in a multiethnic sample of 2,984 breast cancer cases, 4,376 prostate cancer cases, and 7,545 controls (Haiman_2013_PMID: 23555315). The p.Arg883Cys variant was not found to be significantly associated with breast or prostate cancer (Haiman_2013_PMID: 23555315). The p.Arg883 residue is conserved in mammals but not in more distantly related organisms, and four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) suggest that the R variant may impact the protein; however, this information is not predictive enough to assume pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. References Haiman CA et al. Genome-wide testing of putative functional exonic variants in relationship with breast and prostate cancer risk in a multiethnic population. PLoS Genet. 2013 Mar;9(3):e1003419. doi: 0.1371/journal.pgen.1003419. Epub 2013 Mar 28. PMID: 23555315 Mandelker D et al. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA. 2017 Sep 5;318(9):825-835. doi: 10.1001/jama.2017.11137. PMID: 28873162 Maxwell KN et al. Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. Genet Med. 2015 Aug;17(8):630-8. doi: 10.1038/gim.2014.176. Epub 2014 Dec 11. PubMed PMID:25503501

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.